Article • Challenging bias, securing futures
Europe’s critical choice on lung cancer screening: from evidence to action
The scientific case for lung cancer screening with low-dose CT is now firmly established – the challenge lies in translating this evidence into organised, accessible and sustainable programmes across Europe’s diverse healthcare systems. Speaking at a symposium organised by Coreline during the World Conference on Lung Cancer (WCLC 2026) in Seoul, South Korea, Professor Annemiek Snoeckx outlined how countries can move from intention to implementation whilst ensuring quality and equity.
By Mélisande Rouger

© Kwinten Verspeurt
‘Europe doesn’t need a single screening programme, but a shared ambition: to provide high-quality lung cancer screening to every person at high risk, regardless of where they live,’ said Snoeckx, an associate professor of radiology at Antwerp University and Chair of the Radiology Department at Antwerp University Hospital in Belgium.
A pivotal political milestone came on 9 December 2022, when lung cancer screening was included for the first time in the revised European Council recommendation on cancer screening. ‘The wording didn’t go as far as many specialists in the field had hoped, but its significance was nevertheless substantial,’ Snoeckx explained. ‘Lung cancer screening had entered the European political agenda.’
While the European Union cannot dictate how healthcare is organised within individual member states, it can shape the environment in which change takes place – providing scientific recommendations, supporting research, contributing to guidelines and quality standards, and creating frameworks for data sharing and collaboration. Bringing lung cancer screening into this European framework has given implementation new political momentum.
Progress at varying speeds
‘Across Europe, countries are now moving at very different speeds, from established national programmes to large pilots, implementation preparation and more limited early-stage activity,’ Snoeckx noted. Croatia has operated organised screening for several years, whilst extensive screening activity is taking place in the UK. France is also advancing with a large-scale implementation project involving 20,000 participants and different invitation strategies.
The institution paying for prevention is not necessarily the institution receiving its economic benefit
Annemiek Snoeckx
The diversity of European healthcare systems remains one of the defining challenges. Responsibility for screening may sit at national level, with regions or federal states, with insurers, local healthcare organisations or cancer networks. The same scientific evidence therefore encounters very different structures depending on the country.
Belgium illustrates this complexity. ‘Prevention and screening are financed at regional level, while some of the return on that investment may benefit the federal healthcare system,’ Snoeckx explained. ‘The institution paying for prevention is not necessarily the institution receiving its economic benefit.’ Such structural questions can directly influence whether a screening programme moves from intention to implementation.
AI as a solution for workforce constraints
Scaling screening inevitably raises concerns about workforce capacity, particularly in radiology. Yet Snoeckx challenged the assumption that a shortage of radiologists should become a reason to delay implementation.
‘Artificial intelligence is already being used as a second reader and increasingly explored as a potential first reader to help distinguish the large proportion of normal examinations from those requiring closer radiological attention,’ she said. ‘Used appropriately, this could allow radiologists to focus their expertise where it adds the greatest value.’
The discussion should go beyond image interpretation alone, she argued. ‘Efficiency needs to be considered across the entire screening pathway.’
Lessons from Flanders
Snoeckx is leading the ZORALCS trial to evaluate the implementation of lung cancer screening in Flanders. In the programme, participants can use a digital identity to access a platform, assess their eligibility through a risk prediction model and schedule an appointment before attending the hospital for screening.
The team initially worried that such a digital pathway could exclude people with lower levels of education. Early experience, however, showed significant participation from this group, supported by substantial investment in information and first-line assistance.
‘There won’t be one technological solution capable of resolving every bottleneck,’ Snoeckx said. ‘The opportunity instead lies in gaining efficiency step by step – from recruitment and eligibility assessment to image analysis, reporting and follow-up. Taken together, these improvements could make large-scale screening more realistic within existing European resources.’
Overcoming stigma and political short-termism
Prevention also carries a particular political challenge: its benefits often emerge over years, while political decision-making tends to operate over much shorter cycles
Annemiek Snoeckx
Technology is only part of the equation. Stigma remains one of the most persistent obstacles facing lung cancer screening, alongside challenges related to smoking cessation, additional findings and the difficulty of persuading policymakers to invest in prevention when healthcare budgets are already under pressure.
‘Prevention also carries a particular political challenge: its benefits often emerge over years, while political decision-making tends to operate over much shorter cycles,’ Snoeckx observed. ‘Yet unresolved questions should not become an argument for postponing screening. The scientific evidence is established, policy support is developing and implementation is already underway in many parts of Europe.’
The next stage will therefore be less about demonstrating that lung cancer screening can save lives than about ensuring that health systems are capable of delivering it at scale, with consistent quality and equitable access, she concluded.
Profile:
Annemiek Snoeckx, MD, PhD, is Associate Professor at the University of Antwerp and Chair of the Radiology Department at Antwerp University Hospital in Belgium. Her research focuses on thoracic imaging, lung cancer screening and the clinical application of artificial intelligence. She is the principal investigator of the ZORALCS trial evaluating lung cancer screening implementation in Flanders, co-founder of the Flemish Lung Cancer Screening Taskforce, Vice President of the European Society of Thoracic Imaging (ESTI), and Academy Director of the European Diploma in Radiology.
18.11.2026



